Compounders Research Compare

Pharvaris N.V.(PHVS)

Biotechnology · Zug, ZH

$31.21+0.72 (+2.36%)

Delayed quote: Oct 6, 2026, 2:25 PM EDT

About Pharvaris N.V.

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Zug, ZH

148 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Berndt Modig

View full financials

Earnings Yield: N/A

Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The earnings yield is N/A as of 2026-10-06T18:27:58.279Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:27:58.279Z.

Quote observation: 2026-10-06T18:25:12.000Z. Amounts in USD. The price header may show a later quote.

Unrounded diluted TTM EPS · period ending 2026-06-30: -3.1362133
Quote price: 31.21

FMP input reference: 2e72a758e634708c28c06ae15f1e09243225437df43ff658102191b35b06d910

P/E Ratio|FCF Yield|Dividend Yield|All Metrics

PHVS Earnings Yield Metrics

EARNINGS YIELD

N/A

PHVS Competitors' Earnings Yield

Pharvaris N.V.

Current

Market Cap

$2.18B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SELLAS Life Sciences Group, Inc.

Market Cap

$2.14B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GeneDx Holdings Corp.

Market Cap

$2.13B

Earnings Yield

N/A

TTM Avg

0.04%

3Y Avg

0.04%

5Y Avg

0.04%

Maravai LifeSciences Holdings, Inc.

Market Cap

$2.24B

Earnings Yield

N/A

TTM Avg

17.44%

3Y Avg

11.75%

5Y Avg

10.98%

Addus HomeCare Corporation

Market Cap

$2.11B

Earnings Yield

5.04%

TTM Avg

4.80%

3Y Avg

4.13%

5Y Avg

3.70%

Vera Therapeutics, Inc.

Market Cap

$2.08B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Harmony Biosciences Holdings, Inc.

Market Cap

$2.29B

Earnings Yield

7.80%

TTM Avg

8.59%

3Y Avg

7.87%

5Y Avg

6.37%

Vericel Corporation

Market Cap

$2.08B

Earnings Yield

1.15%

TTM Avg

0.84%

3Y Avg

0.48%

5Y Avg

0.48%

Celldex Therapeutics, Inc.

Market Cap

$2.07B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Alvotech

Market Cap

$2.07B

Earnings Yield

N/A

TTM Avg

3.77%

3Y Avg

3.77%

5Y Avg

3.77%

NAME	MARKET CAP	EARNINGS YIELD	TTM	3Y	5Y
Pharvaris N.V. (PHVS)	$2.18B	N/A	N/A	N/A	N/A
SELLAS Life Sciences Group, Inc. (SLS)vs ›	$2.14B	N/A	N/A	N/A	N/A
GeneDx Holdings Corp. (WGS)vs ›	$2.13B	N/A	0.04%	0.04%	0.04%
Maravai LifeSciences Holdings, Inc. (MRVI)vs ›	$2.24B	N/A	17.44%	11.75%	10.98%
Addus HomeCare Corporation (ADUS)vs ›	$2.11B	5.04%	4.80%	4.13%	3.70%
Vera Therapeutics, Inc. (VERA)vs ›	$2.08B	N/A	N/A	N/A	N/A
Harmony Biosciences Holdings, Inc. (HRMY)vs ›	$2.29B	7.80%	8.59%	7.87%	6.37%
Vericel Corporation (VCEL)vs ›	$2.08B	1.15%	0.84%	0.48%	0.48%
Celldex Therapeutics, Inc. (CLDX)vs ›	$2.07B	N/A	N/A	N/A	N/A
Alvotech (ALVO)vs ›	$2.07B	N/A	3.77%	3.77%	3.77%

Earnings Yield vs P/E Ratio

Earnings Yield

N/A

EPS ÷ Price

P/E Ratio

N/A

Price ÷ EPS

Formula: Earnings Yield = (EPS / Price) × 100

Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.

How earnings yield is used:

It expresses earnings relative to share price as a percentage
It can be compared with FCF yield and dividend yield
It can be compared with bond yields because both are percentages
It is mathematically the inverse of the P/E ratio

Earnings Yield Formula & Definition

Earnings Yield = EPS (TTM) / Share Price

Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Yield Dividend Yield All Metrics